For example, one potential application is the development of risk stratification schemes for EGFR+ NSCLC, for which the data of both patient subsets could be merged together in order to derive an algorithm that will then be equally applicable to both. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.